Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) EPS (Basic) (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed EPS (Basic) for 16 consecutive years, with -$0.23 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 89.45% to -$0.23 in Q3 2025 year-over-year; TTM through Sep 2025 was $4.25, a 105.62% increase, with the full-year FY2024 number at -$2.53, up 97.7% from a year prior.
  • EPS (Basic) was -$0.23 for Q3 2025 at NovaBay Pharmaceuticals, up from -$2.39 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $5.43 in Q4 2024 to a low of -$44.43 in Q2 2023.
  • A 5-year average of -$6.96 and a median of -$1.37 in 2024 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): plummeted 17000.0% in 2021, then skyrocketed 112.89% in 2024.
  • NovaBay Pharmaceuticals' EPS (Basic) stood at -$5.13 in 2021, then rose by 6.82% to -$4.78 in 2022, then tumbled by 781.38% to -$42.13 in 2023, then skyrocketed by 112.89% to $5.43 in 2024, then tumbled by 104.24% to -$0.23 in 2025.
  • Per Business Quant, the three most recent readings for NBY's EPS (Basic) are -$0.23 (Q3 2025), -$2.39 (Q2 2025), and $1.44 (Q1 2025).